{"schema_version":"secwatch.filing_event.v1","accession":"0001962918-24-000030","form_type":"8-K","ticker":null,"cik":"0001962918","company_name":"ACELYRIN, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.385446+00:00","generated_at":"2026-06-04T06:43:19.224259+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ACELYRIN reports FY 2023 net loss of $381.6M; cash $721.3M; pipeline progress with izokibep and lonigutamab","bullets":["Net loss $381.6M in 2023 vs $64.8M in 2022; R&D expenses $355.9M including $123.1M IPR&D from ValenzaBio acquisition.","Cash, equivalents and marketable securities $721.3M expected to fund operations into 2026 through late-stage registrational studies.","Positive Phase 1/2 data for lonigutamab (subcutaneous anti-IGF-1R) in thyroid eye disease with rapid proptosis improvements at 3 weeks.","Phase 2b/3 trial of izokibep met primary endpoint ACR50 at 16 weeks with high statistical significance in psoriatic arthritis; HS Phase 3 topline data expected H2 2024.","Appointed Agnes Lee as SVP IR and Corporate Communications; Lynn Tetrault joined Board in December 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001962918-24-000030","json":"https://secwatch.observer/filing/0001962918-24-000030.json","markdown":"https://secwatch.observer/filing/0001962918-24-000030.md","text":"https://secwatch.observer/filing/0001962918-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962918/000196291824000030/0001962918-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962918/000196291824000030/slrn-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:43:19.224259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"58d3dcb09efa91b27da1c4ca7285a5c1cd821373","claim":"ACELYRIN, Inc. reported the full year ended December 31, 2023 results: net income Net loss for the full year ended December 31, 2023 was $381.6 million, compared to $64.8 million for 2022..","evidence_excerpt":"On March 28, 2024, ACELYRIN, INC. (the \" Company \") issued a press release announcing its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1962918/000196291824000030/0001962918-24-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the full year ended December 31, 2023 was $381.6 million, compared to $64.8 million for 2022."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}